- Conditions
- Breast Cancer, Cancer of Breast, Breast Carcinoma
- Interventions
- Palbociclib, Letrozole, Trastuzumab, Goserelin, Breast surgery, Research tumor biopsy, Research bone marrow (OPTIONAL), Research blood sample, Research blood for germline DNA, Blood for detection of circulating tumor cells
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • St Louis, Missouri • Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- Palbociclib 125mg
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Breast Cancer
- Interventions
- Ribociclib, Letrozole, Goserelin, Leuprolide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 71
- States / cities
- Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 74 more
- Conditions
- Breast Cancer
- Interventions
- Ribociclib, Anastrozole, Letrozole, Goserelin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 14
- States / cities
- Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, flutamide, goserelin acetate, leuprolide acetate, SU5416, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • LaGrange, Illinois
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
- Interventions
- Biospecimen Collection, Electronic Health Record Review, Goserelin, Leuprolide, Questionnaire Administration
- Procedure · Other · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
- Interventions
- Tamoxifen, Ribociclib, Goserelin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Prostate Cancer
- Interventions
- Degarelix, Goserelin, Bicalutamide
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 16 more
- Conditions
- Cancer of Prostate
- Interventions
- LY01005, Zoladex
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Anniston, Alabama • Aventura, Florida • Pompano Beach, Florida + 2 more
- Conditions
- Cancer, Prostate Neoplasms
- Interventions
- Leuprolide or goserelin, Transdermal estradiol
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer
- Interventions
- Goserelin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 15 Years to 46 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Metastatic Breast Cancer
- Interventions
- Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 59 Years · Female only
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 35
- States / cities
- Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more
- Conditions
- Breast Cancer
- Interventions
- Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
- Conditions
- Prostate Cancer
- Interventions
- Degarelix, Goserelin acetate
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 859 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 36
- States / cities
- Homewood, Alabama • Little Rock, Arkansas • Fresno, California + 32 more
- Conditions
- Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Interventions
- (Z)-endoxifen, goserelin
- Drug
- Lead sponsor
- Atossa Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
- Conditions
- Metabolic Syndrome
- Interventions
- Zoladex, Testosterone gel, Anastrozole Pill, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 50 Years to 75 Years · Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Musculoskeletal Injury, Hypogonadism, Hormonal Contraception
- Interventions
- Goserelin 3.6 MG, Multi-Stressor Training, Testosterone gel (AndroGel 5g), Testosterone gel (AndroGel 1.25g)
- Drug · Other
- Lead sponsor
- Bradley Nindl
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Radiation Therapy, Bicalutamide, Leuprolide, Goserelin, Flutamide, Questionnaire
- Procedure · Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hormone-sensitive Metastatic Breast Cancer
- Interventions
- OSI-906, Erlotinib, Letrozole, Goserelin
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Franklin, Tennessee • Nashville, Tennessee
- Conditions
- Metastatic Prostate Cancer, Androgen Deprivation Therapy
- Interventions
- GnRH agonist
- Drug
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Salivary Gland Carcinoma
- Interventions
- Goserelin Acetate, Pembrolizumab
- Drug
- Lead sponsor
- Manish Patel
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 3 more
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Endocrine Therapy (ET)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
- Conditions
- HER2 Negative Breast Cancer
- Interventions
- Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy
- Drug · Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut